Biomarkers: Busting blockbusters?

Fueled by the discovery of new biomarkers, personalized medicine will cause diagnostic and pharmaceutical companies to shift their thinking about new products, and eventually perhaps to adopt a radically new business model.

Mario Ehlers
Register for free to listen to this article
Listen with Speechify
A biomarker is any biological indicator that pre­dicts or signals, with a high degree of reliability, some underlying biological state. The number of potential biomarker proteins, genes, metabo­lites, and other molecules has increased in recent years from a few dozen to perhaps several hun­dred. Many more will no doubt be discovered.
Fueled by the discovery of new biomarkers, personalized medicine will cause diagnostic and pharmaceutical companies to shift their think­ing about new products, and eventually perhaps to adopt a radically new business model. All things being equal, the more personalized the treatment, the smaller the patient population and the less attractive the business opportunity. Which begs the question: Is the end approach­ing for the pharmaceutical blockbuster model?
A common misconception regarding per­sonalized medicine is that it will end the block­buster drug model as we know it. According to this reasoning, biomarker tests, by identifying and eliminating non-responding individuals from clinical trials and treatment, will neces­sarily shrink markets for many drugs, perhaps to below profitable levels.
While some observers have expressed mixed feelings about targeted or personalized thera­pies, regulators and the pharm/biotech indus­tries have been doing their best to present the "glass half full" perspective, a position that Pacific Biometrics agrees with.
Along with its inevitable challenges, per­sonalized medicine and drug-diagnostic com­bination products present vast opportunities. Novel, disease-specific biomarkers will greatly streamline drug discovery and clinical develop­ment. We are already seeing this in the form of gene and protein chips that screen patients for dozens (or thousands) of disease-relevant bio­markers. Considerable progress is being made in the area of metabolo­mics as well.
Rapid, high-through­put screening methods can identify drugs most likely to succeed for specific patient popu­lations, enabling com­panies to out-license or drop projects that do not meet their finan­cial objectives even before undertaking animal studies. During clinical trials, similar techniques can identify patients most likely to respond or who might be prone to serious adverse events, thus streamlining human test­ing by perhaps several years. To its credit, FDA's position thus far has been to support the use of biomarkers, in particular pharmacoge­nomics, and to encourage drug developers to submit such data.
Personalized medicine will create many opportunities for developing drugs that are effective in individuals who do not respond to traditional medicines. Such medications would probably qualify as "orphan" products on the basis of their limited patient base. Granted to drugs that treat diseases with fewer than 200,000 patients, orphan status provides extended mar­ket exclusivity, tax breaks, exemption from user fees, availability of grants to cover the cost of clinical trials, and other benefits.
The advent of personalized medicine will by no means be free of risk. There will be win­ners and losers, as well there should be. Drugs that are safer and more effective will move to the head of the class; those that are effective but carry a higher potential for serious side effects will be reserved for patients who do not respond to first-line therapies. And niche drugs, which may only be safe and effective in a very small number of patients, will be limited to those patients.
Using the safest, most effective medicines in the most appropriate patient populations is not just good medicine, it makes good macro-economic sense, and it is hoped good business sense as well. The penalty society pays for inap­propriately prescribed drugs are huge: Adverse drug events are the fourth leading cause of death in the United States and cost the health­care system $200 billion per year.
As the enabling technology for personalized or targeted therapies, biomarkers will continue to be a top priority for both academic and indus­trial biomedicine. While the scientific compo­nents of biomarkers—genomics, proteomics, metabolomics and diagnostic imaging—have deepened our understanding of the biology of disease and treatment, developing these meth­ods into reliable diagnostic tools is an ongoing project.
Mario Ehlers, CMO of Seattle, Wash.-based Pacific Biometrics, is author of more than 50 scientific publications and 5 patent applications.

Mario Ehlers

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue